Adrenergic drugs blockers or enhancers for cognitive decline? What to choose for Alzheimer’s disease patients?

Grazia D. Femminella, Dario Leosco, Nicola Ferrara, Giuseppe Rengo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The adrenergic system has an important role in normal central nervous system function as well as in brain disease. The locus coeruleus, the main source of norepinephrine in brain, is involved in the regulation of learning and memory, reinforcement of sleep-wake cycle and synaptic plasticity. In Alzheimer’s disease, locus coeruleus degeneration is observed early in the course of the disease, years before the onset of clinical cognitive signs, with neurofibrillary detected at the stage of mild cognitive impairment, preceding amyloid deposition. Thus, in the last years, a great interest has grown in evaluating the possibility of central adrenergic system modulation as a therapeutic tool in Alzheimer’s disease. However, evidences do not show univocal results, with some studies suggesting that adrenergic stimulation might be beneficial in Alzheimer’s Disease and some others favoring adrenergic blockade. In this review, we summarize data from both hypothesis and describe the pathophysiological role of the adrenergic system in neurodegeneration.

Original languageEnglish
Pages (from-to)665-671
Number of pages7
JournalCNS and Neurological Disorders - Drug Targets
Volume15
Issue number6
Publication statusPublished - Aug 1 2016

Fingerprint

Adrenergic Antagonists
Adrenergic Agents
Alzheimer Disease
Locus Coeruleus
Neuronal Plasticity
Brain Diseases
Amyloid
Norepinephrine
Sleep
Central Nervous System
Cognitive Dysfunction
Learning
Brain

Keywords

  • Adrenergic receptors
  • Alzheimer’s disease
  • Beta-blockers
  • Functional recovery
  • Locus coeruleus
  • Neurodegeneration

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

Adrenergic drugs blockers or enhancers for cognitive decline? What to choose for Alzheimer’s disease patients? / Femminella, Grazia D.; Leosco, Dario; Ferrara, Nicola; Rengo, Giuseppe.

In: CNS and Neurological Disorders - Drug Targets, Vol. 15, No. 6, 01.08.2016, p. 665-671.

Research output: Contribution to journalArticle

@article{fec78d9866fb480ebc027b4b5f72ec3d,
title = "Adrenergic drugs blockers or enhancers for cognitive decline? What to choose for Alzheimer’s disease patients?",
abstract = "The adrenergic system has an important role in normal central nervous system function as well as in brain disease. The locus coeruleus, the main source of norepinephrine in brain, is involved in the regulation of learning and memory, reinforcement of sleep-wake cycle and synaptic plasticity. In Alzheimer’s disease, locus coeruleus degeneration is observed early in the course of the disease, years before the onset of clinical cognitive signs, with neurofibrillary detected at the stage of mild cognitive impairment, preceding amyloid deposition. Thus, in the last years, a great interest has grown in evaluating the possibility of central adrenergic system modulation as a therapeutic tool in Alzheimer’s disease. However, evidences do not show univocal results, with some studies suggesting that adrenergic stimulation might be beneficial in Alzheimer’s Disease and some others favoring adrenergic blockade. In this review, we summarize data from both hypothesis and describe the pathophysiological role of the adrenergic system in neurodegeneration.",
keywords = "Adrenergic receptors, Alzheimer’s disease, Beta-blockers, Functional recovery, Locus coeruleus, Neurodegeneration",
author = "Femminella, {Grazia D.} and Dario Leosco and Nicola Ferrara and Giuseppe Rengo",
year = "2016",
month = "8",
day = "1",
language = "English",
volume = "15",
pages = "665--671",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Adrenergic drugs blockers or enhancers for cognitive decline? What to choose for Alzheimer’s disease patients?

AU - Femminella, Grazia D.

AU - Leosco, Dario

AU - Ferrara, Nicola

AU - Rengo, Giuseppe

PY - 2016/8/1

Y1 - 2016/8/1

N2 - The adrenergic system has an important role in normal central nervous system function as well as in brain disease. The locus coeruleus, the main source of norepinephrine in brain, is involved in the regulation of learning and memory, reinforcement of sleep-wake cycle and synaptic plasticity. In Alzheimer’s disease, locus coeruleus degeneration is observed early in the course of the disease, years before the onset of clinical cognitive signs, with neurofibrillary detected at the stage of mild cognitive impairment, preceding amyloid deposition. Thus, in the last years, a great interest has grown in evaluating the possibility of central adrenergic system modulation as a therapeutic tool in Alzheimer’s disease. However, evidences do not show univocal results, with some studies suggesting that adrenergic stimulation might be beneficial in Alzheimer’s Disease and some others favoring adrenergic blockade. In this review, we summarize data from both hypothesis and describe the pathophysiological role of the adrenergic system in neurodegeneration.

AB - The adrenergic system has an important role in normal central nervous system function as well as in brain disease. The locus coeruleus, the main source of norepinephrine in brain, is involved in the regulation of learning and memory, reinforcement of sleep-wake cycle and synaptic plasticity. In Alzheimer’s disease, locus coeruleus degeneration is observed early in the course of the disease, years before the onset of clinical cognitive signs, with neurofibrillary detected at the stage of mild cognitive impairment, preceding amyloid deposition. Thus, in the last years, a great interest has grown in evaluating the possibility of central adrenergic system modulation as a therapeutic tool in Alzheimer’s disease. However, evidences do not show univocal results, with some studies suggesting that adrenergic stimulation might be beneficial in Alzheimer’s Disease and some others favoring adrenergic blockade. In this review, we summarize data from both hypothesis and describe the pathophysiological role of the adrenergic system in neurodegeneration.

KW - Adrenergic receptors

KW - Alzheimer’s disease

KW - Beta-blockers

KW - Functional recovery

KW - Locus coeruleus

KW - Neurodegeneration

UR - http://www.scopus.com/inward/record.url?scp=84981517805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981517805&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84981517805

VL - 15

SP - 665

EP - 671

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 6

ER -